Description
QuidelOrtho’s $80 Million Turnaround Plan: Can It Overcome China’s 45% Sales Collapse?
QuidelOrtho reported third-quarter 2026 revenue of $619 million, declining 12% year-over-year due to persistent China headwinds and weak respiratory testing demand. Excluding China, respiratory, and the winding-down U.S. Donor Screening business, revenue increased 3%. Labs and Immunohematology, representing approximately 70% to 75% of revenue outside China, maintained low to mid-single-digit organic growth. Labs revenue outside China rose 4%, supported by Latin America, Japan, and Asia Pacific, while Immunohematology grew 3%. China revenue declined 45% due to distributor destocking and inventory reductions following finalized nationwide IVD pricing guidelines. These guidelines broadly eliminate methodology-based pricing differentiation, with provincial implementation expected from late 2026 and increasing pricing pressure anticipated in 2027. China’s revenue contribution is projected to decline from approximately 8% in 2026 to 4% to 5% in 2027. Point of Care revenue fell 27%, including a 39% decline in respiratory testing.



